[
  {
    "ts": null,
    "headline": "FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria",
    "summary": "The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.",
    "url": "https://finnhub.io/api/news?id=64ef2325144e37b7b21deb71a222064a0254a0f28f9aa1c3be74893f22fe0731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731692431,
      "headline": "FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria",
      "id": 131375194,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_2475675339-e1731681084784.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.",
      "url": "https://finnhub.io/api/news?id=64ef2325144e37b7b21deb71a222064a0254a0f28f9aa1c3be74893f22fe0731"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=9ba50d1098853526edf9b7ba72c474b823688cda5ff61dfc0c913edce8a8aa32",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731689100,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 131418665,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=9ba50d1098853526edf9b7ba72c474b823688cda5ff61dfc0c913edce8a8aa32"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi Get New FDA Review of Dupixent for CSU",
    "summary": "Regeneron, Sanofi Get New FDA Review of Dupixent for CSU",
    "url": "https://finnhub.io/api/news?id=e3cfff9ba9311778c1b476dd8f6c5801a3039ed805552f5451db5347e760e31f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731651120,
      "headline": "Regeneron, Sanofi Get New FDA Review of Dupixent for CSU",
      "id": 131418666,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron, Sanofi Get New FDA Review of Dupixent for CSU",
      "url": "https://finnhub.io/api/news?id=e3cfff9ba9311778c1b476dd8f6c5801a3039ed805552f5451db5347e760e31f"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)",
    "summary": "Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administ",
    "url": "https://finnhub.io/api/news?id=d84903ecf355e4509d46da967a05e5c63736314c7c3b0c4cf11fa3d80f8593df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731650340,
      "headline": "Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)",
      "id": 131366241,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administ",
      "url": "https://finnhub.io/api/news?id=d84903ecf355e4509d46da967a05e5c63736314c7c3b0c4cf11fa3d80f8593df"
    }
  }
]